Indicaid and OSOM COVID-19/FLU A/B Rapid Test Promo Package

The OSOM Ultra Plus Flu A & B Test is an in vitro rapid qualitative test that detects influenza type A and type B nucleoprotein antigens directly from nasal swab and nasopharyngeal swab specimens obtained from patients with signs and symptoms of respiratory infection.

• Meets the Influenza reclassification requirements for rapid antigen tests*
  • Influenza A
    • Sensitivity: 90.3%
    • Specificity: 96.7%
  • Influenza B
    • Sensitivity: 88%
    • Specificity: 99.2%

The INDICAID™ COVID-19 Rapid Antigen Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first five (5) days of symptom onset. Anterior nasal swab specimens may be collected by a healthcare provider (HCP) or self-collected (by individuals 18 years of age or older, under the supervision of an HCP). Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate complexity, high complexity, or waived tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The INDICAID™ COVID-19 Rapid Antigen Test does not differentiate between SARS-CoV and SARS-CoV-2 viruses.